Sign In
Buy NUVL
$90.18
-1.17 (-1.28%)
At Close: Jun 03, 2026
Company to host webcast and conference call on November 17, 2025 at 8:00am ET CAMBRIDGE, Mass. , Nov. 14, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical compan
Nuvalent: Interesting Product, But Aggressive Valuation
09:28pm, Tuesday, 04'th Nov 2025
NUVL is approaching the precipice of a first targeted therapy approval in lung cancer. They also have an increasingly deep pipeline of therapies, with an audacious phase 3 trial spinning up in ALK-pos
Encore pivotal efficacy and safety data from the ARROS-1 trial also to be presented during poster session CAMBRIDGE, Mass. , Nov. 4, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-sta
Cwm LLC Raises Stock Position in Nuvalent, Inc. $NUVL
04:42am, Saturday, 01'st Nov 2025
Cwm LLC boosted its holdings in Nuvalent, Inc. (NASDAQ: NUVL) by 253.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SE
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results
06:30am, Thursday, 30'th Oct 2025
Completed rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC On track to report topline pivotal data for neladalkib in TKI pre-treated advanced ALK-positive NSCLC
Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025
06:00am, Saturday, 18'th Oct 2025
Encouraging preliminary activity observed across diverse set of advanced ALK-positive solid tumors Global enrollment ongoing for adult and adolescent patients with advanced ALK-positive solid tumors b
KLP Kapitalforvaltning AS Buys 1,600 Shares of Nuvalent, Inc. $NUVL
03:56am, Saturday, 18'th Oct 2025
KLP Kapitalforvaltning AS grew its stake in shares of Nuvalent, Inc. (NASDAQ: NUVL) by 23.5% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commissi
CAMBRIDGE, Mass. , Oct. 13, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven ki
Nuvalent, Inc. (NUVL) Presents at UBS Virtual Oncology Day Transcript
06:22pm, Wednesday, 01'st Oct 2025
Nuvalent, Inc. (NASDAQ:NUVL ) UBS Virtual Oncology Day October 1, 2025 3:30 PM EDT Company Participants James Porter - CEO, President & Director Alexandra Balcom - CFO & Treasurer Conference Call Part
Nuvalent to Participate in the UBS 2025 Virtual Oncology Day
06:30am, Wednesday, 24'th Sep 2025
CAMBRIDGE, Mass. , Sept. 24, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven ki
Rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC initiated under FDA's RTOR program, with completion on track for the third quarter of 2025 CAMBRIDGE, Mass. , Se
Nuvalent to Participate in the Cantor Global Healthcare Conference 2025
06:30am, Thursday, 28'th Aug 2025
CAMBRIDGE, Mass. , Aug. 28, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven ki
CAMBRIDGE, Mass. , Aug. 13, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven ki
Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of 2025 Initiated ALKAZAR Phase 3 randomiz
CAMBRIDGE, Mass. , July 21, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kina
